This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Donepezil

Authoring team

Donepezil drug is indicated in the symptomatic treatment of mild to moderate Alzheimer's disease (AD).

  • acetylcholinesterase (AChE) inhibitors increase the concentration of acetylcholine at sites of neurotransmission
  • donepezil is a specific and reversible inhibitor of AChE, licensed in the UK at a dosage of 5 mg/day and 10 mg/day. It is licensed for the symptomatic treatment of people with mild to moderately severe Alzheimer's dementia

See NICE guidance for use in treatment of Alzheimer's disease.

Notes:

  • donepezil improves cognitive outcomes in patients with Alzheimer's disease (AD). However evidence suggests that in patients with AD, donepezil has no significant beneficial effect for treating agitation, a common associated symptom (2)

Reference:

  1. (1) NICE (November 2006).Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease
  2. (2) Howard RJ et al, Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007 Oct 4; 357(14):1382-92.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.